MTOR and neoplasm: BRAF and RAS rearrangements remain the principal oncogenes, although other mutations, namely, TERT promoter and in TP53, as well as PIK3CA–PTEN–AKT–mTOR pathway and SWI–SNG complex (40), synergistically concur to worse outcomes and can be used in tumor prognostication (41).